GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Otsuka Holdings Co Ltd (FRA:OS1) » Definitions » Research & Development

Otsuka Holdings Co (FRA:OS1) Research & Development : €1,982 Mil (TTM As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is Otsuka Holdings Co Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Otsuka Holdings Co's Research & Development for the three months ended in Mar. 2024 was €445 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 was €1,982 Mil.


Otsuka Holdings Co Research & Development Historical Data

The historical data trend for Otsuka Holdings Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Otsuka Holdings Co Research & Development Chart

Otsuka Holdings Co Annual Data
Trend Mar14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,780.10 1,717.26 1,806.02 1,925.79 1,960.37

Otsuka Holdings Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 474.94 484.06 466.03 587.00 444.51

Otsuka Holdings Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €1,982 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Otsuka Holdings Co  (FRA:OS1) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Otsuka Holdings Co Research & Development Related Terms

Thank you for viewing the detailed overview of Otsuka Holdings Co's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


Otsuka Holdings Co (FRA:OS1) Business Description

Traded in Other Exchanges
Address
2-9 Kanda-Tsukasamachi, Chiyoda-ku, Tokyo, JPN, 101-0048
Otsuka Holdings Co Ltd is a Japan-based company operates in pharmaceuticals, nutraceuticals and consumer products. Business activity of the company includes providing healthcare solutions in the areas of nervous system, oncology, cardiovascular system, respiratory system, infectious disease and others. It is also engaged in the research and development of functional foods and beverages, such as electrolyte drinks, nutritional foods, soy snacks and dietary food. In addition it also operates multiple businesses related to chemicals, transportation, warehousing, and electronic equipment. Geographically, it operates in Japan, North America and in other regions of which Japan accounts for larger share of revenue.

Otsuka Holdings Co (FRA:OS1) Headlines

No Headlines